Xencor Receives $120M From Genentech
socalTECH
FEBRUARY 5, 2019
Monrovia-based biopharmaceuticals technology developer Xencor has received $120M in an upfront payment from Genentech this morning--and up to another $180M in development milestones--as part of a new deal to commercialize an immune activating cytokine based on Xencor's technology.
Let's personalize your content